Log in

Relevant bibliographies by topics / Bioabsorbable stent / Journal articles

Journal articles on the topic 'Bioabsorbable stent'

To see the other types of publications on this topic, follow the link: Bioabsorbable stent.

Author: Grafiati

Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Bioabsorbable stent.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Zhao, Yaping, Zhong Chen, Wayne W. Zhang, Sheng Wang, Yaoguo Yang, and Liao Yang. "Bioabsorbable Drug-Eluting Stent Versus Bare Metal Stent in Iliac Artery Evaluated by Optical Coherence Tomography: An In Vivo Study in Porcine." Vascular and Endovascular Surgery 52, no. 7 (July 16, 2018): 512–19. http://dx.doi.org/10.1177/1538574418783528.

Full text

Abstract:

Objective: This study aimed to compare, using optical coherence tomography (OCT), the outcomes of bioabsorbable drug-eluting stent with those of bare metal stent (BMS) following implantation in porcine iliac artery. Methods: After the placement of BMS and bioabsorbable drug-eluting stents, we used OCT and digital subtraction angiography to investigate stent appositions, arterial neointima, evagination, and restenosis at 1 and 3 months. Results: At 1 and 3 months after stent implantation, OCT study was performed to investigate 32 stents and 21 788 struts. Thirty-three malapposed struts were found in the bioabsorbable drug-eluting stent groups and 2 were found in BMS groups. The average neointimal thickness, area, and in-stent stenosis were significantly lower in bioabsorbable drug-eluting stents than in BMS, while the frequency of malapposed struts was higher in the bioresorbable drug-eluting stent groups. Average neointimal thickness was lower in bioabsorbable drug-eluting stents than in BMS at 1 (0.19 ± 0.09 vs 0.67 ± 0.75 mm; P < .001) and 3 months (0.21 ± 0.08 vs 1.52 ± 0.28 mm; P < .001). Conclusion: Our study suggested that bioabsorbable drug-eluting stent is more effective in decreasing arterial restenosis than BMS in animal models.

APA, Harvard, Vancouver, ISO, and other styles

2

Alexy, Ryan D., and Daniel S. Levi. "Materials and Manufacturing Technologies Available for Production of a Pediatric Bioabsorbable Stent." BioMed Research International 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/137985.

Full text

Abstract:

Transcatheter treatment of children with congenital heart disease such as coarctation of the aorta and pulmonary artery stenosis currently involves the use of metal stents. While these provide good short term results, there are long term complications with their use. Children outgrow metal stents, obligating them to future transcatheter dilations and eventual surgical removal. A bioabsorbable stent, or a stent that goes away with time, would solve this problem. Bioabsorbable stents are being developed for use in coronary arteries, however these are too small for use in pediatric congenital heart disease. A bioabsorbable stent for use in pediatric congenital heart disease needs to be low profile, expandable to a diameter 8 mm, provide sufficient radial strength, and absorb quickly enough to allow vessel growth. Development of absorbable coronary stents has led to a great understanding of the available production techniques and materials such as bioabsorbable polymers and biocorrodable metals. Children with congenital heart disease will hopefully soon benefit from the current generation of bioabsorbable and biocorrodable materials and devices.

APA, Harvard, Vancouver, ISO, and other styles

3

Kobo, Ofer, and Ariel Roguin. "Orsiro: ultrathin bioabsorbable polymer sirolimus-eluting stent." Future Cardiology 15, no. 4 (July 2019): 295–300. http://dx.doi.org/10.2217/fca-2019-0001.

Full text

Abstract:

Recent stent developments aimed to reduce and eliminate the long-term inflammatory response include thinner struts, modifications to stent design and the development of bioresorbable polymers (BP). We aimed to summarize the main findings and to discuss the established and the potential benefits of the Orsiro BP sirolimus-eluting stents in everyday clinical use. We have reviewed the available evidence on the clinical performance of the Orsiro BP drug-eluting stents. Orsiro BP sirolimus-eluting stents is clinically proven and showed noninferiority against major drug-eluting stents and provides high safety and efficacy profile at long-term follow-up. Furthermore, it may be the preferred treatment option in specific subgroups as acute coronary syndrome, as shown in the BIOFLOW V trial.

APA, Harvard, Vancouver, ISO, and other styles

4

Jamshidi, Mehdi, Mahmoud Rajabian, Michael B. Avery, Uttandaraman Sundararaj, Janet Ronsky, Brooke Belanger, John H. Wong, and Alim P. Mitha. "A novel self-expanding primarily bioabsorbable braided flow-diverting stent for aneurysms: initial safety results." Journal of NeuroInterventional Surgery 12, no. 7 (November 27, 2019): 700–705. http://dx.doi.org/10.1136/neurintsurg-2019-015555.

Full text

Abstract:

IntroductionThe advent of metal flow-diverting stents has provided neurointerventionalists with an option for treating aneurysms without requiring manipulations within the aneurysm sac. The large amount of metal in these stents, however, can lead to early and late thrombotic complications, and thus requires long-term antiplatelet agents. Bioabsorbable stents have been postulated to mitigate the risk of these complications. Here we present early data on the first self-expandable primarily bioabsorbable stent for aneurysms.MethodsBraided stents were developed using poly-L-lactic acid fibers with material surface area similar to metal flow diverters. Crush resistance force, hemolysis, and thrombogenicity were determined and compared with existing commercial devices. Stents were deployed in infra-renal rabbit aortas to determine angiographic side branch patency and to study neointima formation for a 1-month follow-up period.ResultsCrush resistance force was determined to be on the order of existing commercial devices. Hemolytic behavior was similar to existing metal devices, and thrombogenicity was lower than metal flow-diverting stents. A smooth neointimal layer was found over the absorbable stent surface and all covered side branches were patent at follow-up.ConclusionThe design of self-expanding primarily bioabsorbable flow-diverting stents is possible, and preliminary safety data is consistent with a favorable profile in terms of mechanical behavior, hemocompatibility, side branch patency, and histological effects. Additional in vitro and long-term in vivo studies are in progress and will help determine aneurysm occlusion rates and absorption characteristics of the stent.

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Si W., Ching-Sung Weng, Shih-Ming Wang, Wei-Jie Wang, and Ming-Chen Wang. "A BIOABSORBABLE, DEGRADABLE STENT WITH A DRUG RELEASE SYSTEM." Biomedical Engineering: Applications, Basis and Communications 30, no. 03 (May 30, 2018): 1850021. http://dx.doi.org/10.4015/s1016237218500217.

Full text

Abstract:

The aim of this study was to develop a bioabsorbable, degradable stent for drug storage that can be produced rapidly. A stent with a length of 28[Formula: see text]mm and a diameter of 6[Formula: see text]mm was generated by injecting polycaprolactone (PCL) (PubChem CID:6452583) into a mold created using a toggle-type microtool machine. Micropores of 0.5[Formula: see text]mm diameter and 0.6[Formula: see text]mm depth were created on stents. A stent had 54 pores, and each pore had a storage volume of 0.1175[Formula: see text]c3. To determine the optimal PCL concentration for stent construction, stents of three PCL concentrations (20%, 25%, and 30%) were fabricated in the experiment, and the material and chemical properties of the stents were determined. In addition, four proportions of PCL:PLGA (10:0, 8:2, 5:5, 0:10) were tested, and the corresponding pore degradation time was employed as a reference parameter for controlling the amount of drug release in the stent design. With an increase in PCL concentration from 20% to 30%, the load increased from 39.718 to 63.5[Formula: see text]N. The stent with 25% PCL concentration exhibited optimal surface roughness ([Formula: see text][Formula: see text]nm). Finally, scanning electron microscopy indicated that the surface of the material with 25% PCL concentration did not contain any fractures and exhibited planar evenness. The results demonstrate the development of a bioabsorbable, degradable stent that can be applied in vascular surgery.

APA, Harvard, Vancouver, ISO, and other styles

6

Shah, Jimil, and Surinder Singh Rana. "Newer Stents for Unresectable Malignant Distal Biliary Obstruction: Striving for Perfection!" Journal of Digestive Endoscopy 12, no. 01 (March 2021): 059–62. http://dx.doi.org/10.1055/s-0041-1728841.

Full text

Abstract:

AbstractEndoscopic biliary stenting is one of the most commonly used palliative procedure in patients with unresectable malignant distal biliary obstruction. Biliary stenting can be performed with either plastic or metallic stents. Stent occlusion and migration are important limitations of currently available stents. Variety of newer stents with varying designs and stent materials like stents with antimigratory properties, antireflux stents, drug-eluting stents, radioactive stents, and bioabsorbable stents are being developed to overcome the limitations of currently available stents. In this article, we are discussing two articles on the newer stent designs (plastic and metal stents) for biliary drainage in patients with unresectable malignant distal biliary obstruction.

APA, Harvard, Vancouver, ISO, and other styles

7

Ference, Elisabeth H., Karam W. Badran, Edward C. Kuan, Marvin Bergsneider, Anthony P. Heaney, and Marilene B. Wang. "Bioabsorbable Steroid Eluting Stents in the Treatment of Recurrent Rathke's Cleft Cyst." Journal of Neurological Surgery Part B: Skull Base 80, no. 05 (December 6, 2018): 505–10. http://dx.doi.org/10.1055/s-0038-1675558.

Full text

Abstract:

Abstract Objectives Bioabsorbable steroid eluting stents may prevent the stenosis of ostia after sinus surgery. We describe a technique utilizing this technology to prevent the reformation of Rathke's cleft cysts (RCC) after transnasal transsphenoidal surgical drainage. Design This study is based on retrospective review. Setting The research took place at Tertiary academic medical center. Participants Patients who underwent endoscopic marsupialization of RCC with stent placement were participated in this study. Main Outcome Measures Demographics, surgical history, outcomes, and complications were primary measures of this study. Results Four patients underwent drainage of a recurrent RCC with subsequent stent placement. All patients consented to off-label use of the stent. The mean age of patients was 42 years old and the number of prior drainage procedures ranged from 1 to 3. The stent was placed directly into the opening of the cyst after drainage with no other tissue placed into the cyst cavity or opening. The stents are bioabsorbable and were not removed after surgery but were evaluated endoscopically at 2 and 6 weeks after surgery. The patients have been followed for a mean of 14 months after surgery with no evidence of recurrence on endoscopic exam or imaging. No patient had cerebrospinal fluid leak during or after the operation or permanent endocrinopathy. Conclusion The use of a bioabsorbable steroid eluting stent had no unanticipated consequences and all drainage pathways of all the RCCs remain patent. The use of this technology may decrease recurrence rates in revision or complex cases where patients have extensive scarring of the operative field from prior drainage procedures. Further follow-up of the current cases and study in a larger cohort are warranted.

APA, Harvard, Vancouver, ISO, and other styles

8

Wu, Yizhe, Li Shen, Qibing Wang, Lei Ge, Jian Xie, Xi Hu, Aijun Sun, Juying Qian, and Junbo Ge. "Comparison of Acute Recoil between Bioabsorbable Poly-L-lactic Acid XINSORB Stent and Metallic Stent in Porcine Model." Journal of Biomedicine and Biotechnology 2012 (2012): 1–8. http://dx.doi.org/10.1155/2012/413956.

Full text

Abstract:

Objective. To investigate acute recoil of bioabsorbable poly-L-lactic acid (PLLA) stent.Background. As newly developed coronary stent, bioabsorbable PLLA stent still encountered concern of acute stent recoil.Methods. Sixteen minipigs were enrolled in our study. Eight PLLA XINSORB stents (Weite Biotechnology Co., Ltd., China) and eight metallic stents (EXCEL, Jiwei Co., Ltd. China) were implanted into coronary arteries. Upon quantitative coronary angiography analysis, acute absolute recoil was defined as the difference between mean diameter of inflated balloon (X) and mean lumen diameter of stent immediately after deployment (Y), while acute percent recoil was defined as (X−Y)/Xand expressed as a percentage. Intravascular ultrasound (IVUS) was performed immediately after implantation and 24 hours later to compare cross-sectional area (CSA) between two groups and detect stent malapposition or collapse.Results. Acute absolute recoil in XINSORB and EXCEL was0.02±0.13 mm and −0.08±0.08 mm respectively (P=0.19). Acute percent recoil in XINSORB and EXCEL was0.66±4.32% and −1.40±3.83%, respectively (P=0.45). CSA of XINSORB was similar to that of EXCEL immediately after implantation, so was CSA of XINSORB at 24-hours followup. Within XINSORB group, no difference existed between CSA after implantation and CSA at 24-hours followup. No sign of acute stent malapposition was detected by IVUS.Conclusions. The acute stent recoil of XINSORB is similar to that of EXCEL. No acute stent malapposition or collapse appeared in both kinds of stent. This preclinical study was designed to provide preliminary data for future studies of long-term efficacy and safety of XINSORB stent.

APA, Harvard, Vancouver, ISO, and other styles

9

Khan, Abdur R., Avnish Tripathi, Talha A. Farid, Bilal Abaid, Deepak L. Bhatt, Jon R. Resar, and Michael P. Flaherty. "Stent thrombosis with bioabsorbable polymer drug-eluting stents." Coronary Artery Disease 28, no. 7 (November 2017): 564–69. http://dx.doi.org/10.1097/mca.0000000000000539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Vorobeva, Yu S., Z. K. Shugushev, A. G. Faibushevich, and D. A. Maximkin. "BIOABSORBABLE SCAFFOLDS FOR PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH CORONARY ARTERY DISEASE: PROBLEMS AND FUTURE PERSPECTIVES." Complex Issues of Cardiovascular Diseases 8, no. 3 (September 26, 2019): 72–84. http://dx.doi.org/10.17802/2306-1278-2019-8-3-72-84.

Full text

Abstract:

Highlights. Bioabsorbable vascular scaffolds for percutaneous coronary interventions in multivessel coronaryartery disease patients and concomitant type 2 diabetes mellitus may increase the effectiveness of endovascular treatment and improve the long-term prognosis. The review article discusses recent data and evidences on the efficacy and safety of various stent generations for treating patients with coronary artery disease. The main complications commonly occurred following the implantation of drug-eluting stents in the long-term period are summarized, suggesting the rationale for the use of the next generation bioabsorbable vascular scaffolds in routine clinical practice. Bioabsorbable vascular scaffolds for endovascular treatment of patients with coronary artery disease show comparable efficacy compared with conventional drug-eluting stents. Particular attention is paid to the technical approaches of bioabsorbable vascular scaffold implantation, the use of intavascular imaging to control the implantation, as well as the timing of dual antiplatelet therapy in the postoperative period. The final term of the first-generation scaffold absorption, dual antiplatelet therapy, the effectiveness of bioabsorbable vascular scaffold-treated distal lesions and safety in patients with type 2 diabetes are highlighted. Future perspectives of using the next generation bioabsorbable vascular scaffolds that may improve the efficiency of percutaneous coronary interventions are presented.

APA, Harvard, Vancouver, ISO, and other styles

11

DI MARIO, CARLO, HUW GRIFFITHS, OMER GOKTEKIN, NICOLAS PEETERS, JAN VERBIST, MARC BOSIERS, Koen DELOOSE, et al. "Drug-Eluting Bioabsorbable Magnesium Stent." Journal of Interventional Cardiology 17, no. 6 (December 2004): 391–95. http://dx.doi.org/10.1111/j.1540-8183.2004.04081.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Saito, Shigeru. "New horizon of bioabsorbable stent." Catheterization and Cardiovascular Interventions 66, no. 4 (2005): 595–96. http://dx.doi.org/10.1002/ccd.20590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Meredith, I. "Bioabsorbable Polymer Stent Noninferior to Permanent Polymer Stent." MD Conference Express 11, no. 14 (December 1, 2011): 9–10. http://dx.doi.org/10.1177/155989771114007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Bioabsorbable Stents May Rescue Troubled Drug-Eluting Stent Sector." Journal of Clinical Engineering 32, no. 1 (January 2007): 10. http://dx.doi.org/10.1097/00004669-200701000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Shugushev, Z. Kh, Daniil A. Maksimkin, Yu S. Vorob’eva, A. G. Chepurnoy, G. I. Veretnik, and A. G. Faibushevich. "Bioabsorbable vascular endoproteases for the treatment of patients with coronary heart disease and type 2 diabetes mellitus." Clinical Medicine (Russian Journal) 95, no. 9 (October 11, 2017): 824–28. http://dx.doi.org/10.18821/0023-2149-2017-95-9-824-828.

Full text

Abstract:

Aim. To evaluate efficiency of endovascular intervention in patients with type 2 diabetes mellitus with the use of bioabsorbable vascular endoproteases and everolimus-coated stents. Material and methods. A total of 143 patients were initially selected for the study of whom 125 were randomized into 2 groups, one including 57 patients with implanted bioabsorbable vascular endoproteases, the other comprised of 68 patients treated with the use of everolimus-coated stents. Inclusion criteria: primary lesion of coronary arteries, stable angina of effort (II-III FC), myocardial ischemia (>10%) confirmed in functional tests, compensated and subcompensated DM2, stenosis of middle and distal segments of the main coronary arteries (≥70%) diagnosed by digital angiography. Exclusion criteria: the target artery not more than 4 mm in diameter, acute coronary syndrome, excess vascular tortuosity, marked calcinosis of coronary arteries, bifurcation lesion, left coronary trunk lesion, history of myocardial revascularization. Criteria for the assessment of immediate outcomes: frequency of major cardiovascular events (death, myocardial infarction, emergency secondary intervention). Criteria for the assessment of long-term outcomes: frequency of major cardiovascular events (death, myocardial infarction, secondary intervention), frequency of in-scaffold/in-stent restenosis or stent thrombosis. Results of biobsorbable scaffold implantation were controlled using optical coherence tomography in the end of surgery and during 12 month during follow-up. Results. A total of 63 bioabsorbable vascular endoprostheses and 102 everolimus-coated stents were implanted to patients of groups 1 and 2 respectively. Mean diameter of the endoprostheses was 2.88±0.06 and 2.68±0.12 mm respectively (р>0,05). The intervention was regarded as technically successful in 100% cases. The overall frequency of major cardiovascular complications during hospitalization in patients of groups 1 and 2 was 3.5 and 2.94% respectively. Long-term outcomes could be estimated in 41 patients of group 1 and 52 ones in group 2. All patients survived for 12 months. The frequency of non-fatal MI was 4.9 and 3.8% in groups 1 and 2 respectively (р>0,05), the cause being progression of atherosclerosis in other arteries. Frequency of in-stent restenosis was 2.4 and 1.9% (р>0,05). Cases of late stent thrombosis were absent whereas coherence tomography revealed severe intravascular volume depletion to 0.14±0.19 and 0.12±0,23 mm in groups 1 and 2 respectively (р>0,05). Conclusion. Bioabsorbable endoprostheses implanted to patients with coronary heart disease and type 2 diabetes mellitus and stenosis of middle and distal segments of the main coronary arteries within 12 months after surgery proved as efficient and safe as everolimus-coated stents.

APA, Harvard, Vancouver, ISO, and other styles

16

Buchanan, Gill Louise, Sandeep Basavarajaiah, and Alaide Chieffo. "Stent Thrombosis: Incidence, Predictors and New Technologies." Thrombosis 2012 (March 11, 2012): 1–12. http://dx.doi.org/10.1155/2012/956962.

Full text

Abstract:

Some concerns have been raised regarding the risk of late and very late stent thrombosis (ST) following drug-eluting stent implantation. Despite remaining an uncommon complication of percutaneous coronary intervention, when ST occurs, it can be catastrophic to the individual, commonly presenting as acute ST elevation myocardial infarction or sudden cardiac death. The incidence and predictors of ST have been reported in the literature and the role of dual antiplatelet therapies in the avoidance of such a complication remains vital. Ongoing studies are assessing the role of these therapies including platelet reactivity testing, genetic testing and optimum duration of therapy. In addition, newer polymer-free and bioabsorbable stents are under investigation in the quest to potentially minimise the risk of ST.

APA, Harvard, Vancouver, ISO, and other styles

17

Onuma, Yoshinobu, Nicolo Piazza, John Ormiston, and Patrick Serruys. "Everolimus-eluting bioabsorbable stent – Abbot Vascular programme." EuroIntervention 5, F (December 2009): F98—F102. http://dx.doi.org/10.4244/eijv5ifa17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Meier, P. "Bioabsorbable drug eluting stent: winner or sinner?" BMJ 347, no. 27 1 (November 27, 2013): f7091. http://dx.doi.org/10.1136/bmj.f7091.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

AGRAWAL, C. MAULI, and HOWARD G. CLARK. "Deformation Characteristics of a Bioabsorbable Intravascular Stent." Investigative Radiology 27, no. 12 (December 1992): 1020–23. http://dx.doi.org/10.1097/00004424-199212000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Korpela, Antti, Pertti Aarnio, Hannu Sariola, Pertti Törmälä, and Ari Harjula. "Bioabsorbable Bronchial Stent in an Animal Model." Journal of Bronchology 5, no. 1 (January 1998): 9–13. http://dx.doi.org/10.1097/00128594-199801000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Colombo, Antonio, and Andrew SP Sharp. "The bioabsorbable stent as a virtual prosthesis." Lancet 373, no. 9667 (March 2009): 869–70. http://dx.doi.org/10.1016/s0140-6736(09)60521-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Franco, R. "A Novel Bioabsorbable Drug-Eluting Tracheal Stent." Yearbook of Otolaryngology-Head and Neck Surgery 2012 (January 2012): 50–52. http://dx.doi.org/10.1016/j.yoto.2012.03.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lim, Gregory B. "DREAMS of a bioabsorbable stent coming true." Nature Reviews Cardiology 10, no. 3 (February 5, 2013): 120. http://dx.doi.org/10.1038/nrcardio.2013.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Zhu, G. H., Anthony H. C. Ng, Subbu S. Venkatraman, Freddy Y. C. Boey, Amilia L. Y. Wee, Scott L. Trasti, and Lynne Hsueh Yee Lim. "A novel bioabsorbable drug-eluting tracheal stent." Laryngoscope 121, no. 10 (August 5, 2011): 2234–39. http://dx.doi.org/10.1002/lary.22175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wykrzykowska, Joanna J., Yoshinobu Onuma, and Patrick W. Serruys. "Advances in stent drug delivery: the future is in bioabsorbable stents." Expert Opinion on Drug Delivery 6, no. 2 (February 2009): 113–26. http://dx.doi.org/10.1517/17425240802668495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Canfield, John, and Hana Totary-Jain. "40 Years of Percutaneous Coronary Intervention: History and Future Directions." Journal of Personalized Medicine 8, no. 4 (October 1, 2018): 33. http://dx.doi.org/10.3390/jpm8040033.

Full text

Abstract:

The field of interventional cardiology has evolved significantly since the first percutaneous transluminal coronary angioplasty was performed 40 years ago. This evolution began with a balloon catheter mounted on a fixed wire and has progressed into bare-metal stents (BMS), first-generation drug-eluting stents (DES), second- and third-generation biodegradable polymer-based DES, and culminates with the advent of bioabsorbable stents, which are currently under development. Each step in technological advancement has improved outcomes, while new persisting challenges arise, caused by the stent scaffolds, the polymers employed, and the non-selective cytostatic and cytotoxic drugs eluted from the stents. Despite the promising technological advances made in stent technology, managing the balance between reductions in target lesion revascularization, stent thrombosis, and bleeding remain highly complex issues. This review summarizes the evolution of percutaneous coronary intervention with a focus on vascular dysfunction triggered by the non-selective drugs eluted from various stents. It also provides an overview of the mechanism of action of the drugs currently used in DES. We also discuss the efforts made in developing novel cell-selective drugs capable of inhibiting vascular smooth muscle cell (VSMC) proliferation, migration, and infiltration of inflammatory cells while allowing for complete reendothelialization. Lastly, in the era of precision medicine, considerations of patients’ genetic variance associated with myocardial infarction and in-stent restenosis are discussed. The combination of personalized medicine and improved stent platform with cell-selective drugs has the potential to solve the remaining challenges and improve the care of coronary artery disease patients.

APA, Harvard, Vancouver, ISO, and other styles

27

Lavigne, Philippe, François Lavigne, and Issam Saliba. "Sustained Inner Ear Steroid Delivery via Bioabsorbable Stent." Otolaryngology–Head and Neck Surgery 155, no. 4 (July 22, 2016): 649–53. http://dx.doi.org/10.1177/0194599816651262.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Jabara, Refat, Lakshmana Pendyala, Sarah Geva, Jack Chen, Nicolas Chronos, and Keith Robinson. "Novel fully bioabsorbable salicylate-based sirolimus-eluting stent." EuroIntervention 5, F (December 2009): F58—F64. http://dx.doi.org/10.4244/eijv5ifa10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lederman, L., and M. I. Kurdi. "Ideal Bioabsorbable Stent Scaffold is an Achievable Dream." MD Conference Express 13, no. 7 (August 1, 2013): 31–32. http://dx.doi.org/10.1177/155989771307016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Lee, J. S., P. Han, E. Song, D. Kim, H. Lee, M. Labowsky, J. Taavitsainen, et al. "Magnetically Coated Bioabsorbable Stents for Renormalization of Arterial Vessel Walls after Stent Implantation." Nano Letters 18, no. 1 (December 28, 2017): 272–81. http://dx.doi.org/10.1021/acs.nanolett.7b04096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Gundogan, Buket, Aaron Tan, Yasmin Farhatnia, Mohammad S. Alavijeh, Zhanfeng Cui, and Alexander M. Seifalian. "Bioabsorbable Stent Quo Vadis: A Case for Nano-Theranostics." Theranostics 4, no. 5 (2014): 514–33. http://dx.doi.org/10.7150/thno.8137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sikora-Jasinska, Malgorzata, Lea M. Morath, Maria P. Kwesiga, Margaret E. Plank, Alexia L. Nelson, Alexander A. Oliver, Martin L. Bocks, Roger J. Guillory, and Jeremy Goldman. "In-vivo evaluation of molybdenum as bioabsorbable stent candidate." Bioactive Materials 14 (August 2022): 262–71. http://dx.doi.org/10.1016/j.bioactmat.2021.11.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Ioseliani, D. G., D. A. Asadov, V. V. Fomenko, A. V. Azarov, and S. P. Semitko. "Five-year outcomes of implantation of Absorb biodegradable stents using the bifurcation stenting technique: a case report." Cardiovascular Therapy and Prevention 20, no. 4 (July 17, 2021): 2864. http://dx.doi.org/10.15829/1728-8800-2021-2864.

Full text

Abstract:

The presented case report describes a five-year outcomes of bifurcation stenting of the left anterior descending artery and large diagonal branch with Absorb bioabsorbable vascular stent (BVS) according to selective coronary angiography and optical coherence tomography. The example demonstrates not only the successful implantation of biodegradable stents into the bifurcation area, but also the complete restoration of the arterial wall with the formation of neocarina. Optical coherence tomography made it possible to study in detail all stages of vascular wall alterations from the inside. This case report prompts a fresh look at the biodegradable BVS Absorb stents and does not rule out the potential of returning these stents to clinical practice in the future. Currently, the production and use of Absorb BVSs has been suspended, but they have filled a certain niche in the endovascular treatment of patients with coronary artery disease.

APA, Harvard, Vancouver, ISO, and other styles

34

Cordunean, Alina, Roxana Hodaş, Sorin Pop, Nora Rat, Laura Jani, Alexandra Stănescu, Imre Benedek, and Theodora Benedek. "Characteristics of Coronary Lesions in Small Vessel Disease Treated with Elective Stenting in Patients with Type 2 Diabetes Mellitus." Journal of Interdisciplinary Medicine 1, no. 1 (June 1, 2016): 55–61. http://dx.doi.org/10.1515/jim-2016-0012.

Full text

Abstract:

Abstract Background: The incidence of diabetes mellitus (DM) has suffered a dramatic increase and is a serious worldwide issue. Diabetes causes microvascular and macrovascular complications including coronary artery disease (CAD) that ultimately contributes to a high rate of cardiovascular morbidity and mortality. Study aim: The aim of this study was to assess the factors associated with the atherosclerotic involvement of small coronary arteries as compared to large vessel disease, in patients with type 2 diabetes mellitus undergoing percutaneous stent coronary angioplasty. Material and methods: Thirty-one patients who underwent Multislice 64 CT assessment of coronary lesions and stent implantation at the level of the significant coronary lesion were included in the study. CT-based Calcium Score was determined in all patients. Group 1 included patients with coronary lesions located on a vessel with a reference diameter above 3 mm (n = 24) and Group 2 included patients with a coronary lesion located on a vessel with a reference diameter below 3 mm (n = 7). Results: The mean age of the study population was 62.25 ± 2.59 years in Group 1 and 64.28 ± 9.18 years in Group 2. Female gender was recorded in 38% of cases in Group 1 and in 14% of cases in Group 2. The left ventricular ejection fraction was below 45% in 13% of cases in Group 1 and in 29% of patients in Group 2. Bioabsorbable stents were implanted in 57% of coronary arteries suffering from small vessel disease, compared to 4% in the rest of the coronary arteries (p = 0.005). The Calcium Score was 552.45 ± 545.79 (95% CI: 354.41–694.64) in Group 1 compared to 1387 ± 1830.3 (95% CI: 305.85–3079.9) (p = 0.014). Conclusions: The location of the atherosclerotic process at the level of the small coronary arteries is associated with a significantly higher Calcium Score at the level of the coronary tree, and with a higher rate of bioabsorbable stent implantation.

APA, Harvard, Vancouver, ISO, and other styles

35

Saito, Yukihito, Kenichirou Minami, Masashi Kobayashi, Yoshihisa Nakao, Hideyasu Omiya, Hiroji Imamura, Noriko Sakaida, and Akiharu Okamura. "New tubular bioabsorbable knitted airway stent: Biocompatibility and mechanical strength." Journal of Thoracic and Cardiovascular Surgery 123, no. 1 (January 2002): 161–67. http://dx.doi.org/10.1067/mtc.2002.118503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Tashiro, Hirotaka, Takayuki Ogawa, Toshiyuki Itamoto, Yuichiro Ushitora, Yoshizato Tanimoto, Akihiko Oshita, Hironobu Amano, and Toshimasa Asahara. "Synthetic Bioabsorbable Stent Material for Duct-to-Duct Biliary Reconstruction." Journal of Surgical Research 151, no. 1 (January 2009): 85–88. http://dx.doi.org/10.1016/j.jss.2008.02.056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kounis, Nicholas G., George D. Soufras, Grigorios Tsigkas, and George Hahalis. "Bioabsorbable stent thrombosis Quo Vadis: Is Kounis syndrome still present?" International Journal of Cardiology 176, no. 2 (September 2014): 305–6. http://dx.doi.org/10.1016/j.ijcard.2014.07.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Alfonso, Fernando, Julio Nuccio, Cecilia Cuevas, Alberto Cárdenas, Nieves Gonzalo, and Pilar Jimenez-Quevedo. "Treatment of Coronary In-Stent Restenosis With Bioabsorbable Vascular Scaffolds." Journal of the American College of Cardiology 63, no. 25 (July 2014): 2875. http://dx.doi.org/10.1016/j.jacc.2013.05.107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Florin Ferent, Ioan, Andras Mester, Ota Hlinomaz, Ladislav Groch, Michal Rezek, Jan Sitar, Jiri Semenka, Martin Novak, and Imre Benedek. "Intracoronary Imaging for Assessment of Vascular Healing and Stent Follow-up in Bioresorbable Vascular Scaffolds." Current Medical Imaging Formerly Current Medical Imaging Reviews 16, no. 2 (January 24, 2020): 123–34. http://dx.doi.org/10.2174/1573405614666180604093621.

Full text

Abstract:

Bioresorbable Vascular Scaffolds (BVS) are polymer-based materials implanted in the coronary arteries in order to treat atherosclerotic lesions, based on the concept that once the lesion has been treated, the material of the implanted stent will undergo a process of gradual resorption that will leave, in several years, the vessel wall smooth, free of any foreign material and with its vasomotion restored. However, after the first enthusiastic reports on the efficacy of BVSs, the recently published trials demonstrated disappointing results regarding long-term patency following BVS implantation, which were mainly attributed to technical deficiencies during the stenting procedure. Intracoronary imaging could play a crucial role for helping the operator to correctly implant a BVS into the coronary artery, as well as providing relevant information in the follow-up period. This review aims to summarize the role of intracoronary imaging in the follow-up of coronary stents, with a particular emphasis on the role of intravascular ultrasound and optical coherence tomography for procedural guidance during stent implantation and also for follow-up of bioabsorbable scaffolds.

APA, Harvard, Vancouver, ISO, and other styles

40

Islam, AHMW, S. Munwar, S. Talukder, AQM Reza, T. Ahmed, AH Bhuiyan, R. Masud, et al. "Bioabsorbable Vascular Scaffolds Eluting with Everolimus: for Percutaneous Coronary Intervention of Patients with de-novo Coronary Artery Lesion: Our Experiences at a Tertiary Hospital." Cardiovascular Journal 6, no. 2 (March 15, 2014): 122–26. http://dx.doi.org/10.3329/cardio.v6i2.18352.

Full text

Abstract:

Background: Aim of the study was to evaluate the primary procedural success of percutaneous coronary intervention (PCI) of de-novo coronary artery lesion by using Bioabsorbable Vascular Scaffold (BVS) ABSORB stents eluting Everolimus. Methods: Total 16 patients were enrolled in this very preliminary study of BVS absorb. Among them, Male: 11 and Female: 5. Total 20 stents were deployed. Mean age were for Male: 56 yrs, for Female: 60 yrs. Associated coronary artery disease (CAD) risk factors were Dyslipidemia, High Blood pressure, Diabetes Mellitus, Positive family history (FH) for CAD and Smoking. Patients were followed up clinically. Results: Among the study group; 13 (81%) were Dyslipidemic, 10(62.5%) were hypertensive; 6 (37.5%) patients were Diabetic, FH 3(18.75%), and 2(18%) were all male smoker. Female patients were more obese [Body Mass Index (BMI) M 25: F 27] and developed CAD in advance age. A common stented territory was for left anterior descending artery (LAD): 6 (37.5%), left circumflex artery (LCX) 5 (25%), right coronary artery (RCA) 6(37.5%). One patient had both LCX and LAD stenting. Total 3 patients had double/overlapping stent in RCA lesion. Territory wise distributions of BVS ABSORB stent were for LAD 6(30%), RCA 9 (45%), and LCX 5 (25%). There was no periprocedural or postprocedural complication. Conclusion: BVS ABSORB Everolimus eluting vascular scaffold showed favorable clinical outcome without any major cardiac events (acute or late stent thrombosis, MI or death) over a period of 9 month. Thus, BVS ABSORB would be favorable alternative to other available drug eluting metallic stents. DOI: http://dx.doi.org/10.3329/cardio.v6i2.18352 Cardiovasc. j. 2014; 6(2): 122-126

APA, Harvard, Vancouver, ISO, and other styles

41

Hwang, Tae In, Seo Yeon Lee, Do Hee Lee, Jun-Kyu Park, Chan Hee Park, and Cheol Sang Kim. "Fabrication of Bioabsorbable Polylactic-Co-Glycolic Acid/Polycaprolactone Nanofiber Coated Stent and Investigation of Biodegradability in Porcine Animal Model." Journal of Nanoscience and Nanotechnology 20, no. 9 (September 1, 2020): 5360–64. http://dx.doi.org/10.1166/jnn.2020.17674.

Full text

Abstract:

Stent-mediated therapy is minimally invasive and fairly effective for the specific tissue and organs with tubal structures such as the esophagus, intestine, and blood vessels. Cerebral arteries are one of the most critical tubal structures to maintain the physiological function and the life of the human. Since the retrieval of the implanted vascular stent is difficult and risky, the one-step stent therapy is imperative. However, the placement of a current pipe-typed stent can also limit the nutritional supply to the vascular wall. Also, the non-degradable polymeric layer is possibly sensitized to the recipient as a foreign body after prolonged period after implantation. Herein, we developed PLGA/PCL nanofiber-coated stent for blocking the flow towards the aneurysm cavity as well as allowing nutritional support to the vessel with the biodegradability. The PLGA/PCL nanofiber-coated stent (NCS) was fabricated via electrospinning composite nanofibers onto a self-expandable mater metal stent. The as-fabricated NCS was physicochemically characterized using FT-IR, FE-SEM, and UTM, and experimented in vivo as implanted in porcine models and radiologically and histologically analyzed. The NCS demonstrated improved physicochemical properties for intracranial aneurysmal treatment including enhanced mechanical properties. The bioabsorbability of NCS was confirmed in the animal model.

APA, Harvard, Vancouver, ISO, and other styles

42

Miyazawa, Mitsuo, Masayasu Aikawa, Takahiro Torii, Katsuya Okada, Yoshihide Otani, Isamu Koyama, and Yoshito Ikada. "evelopment of a Bioabsorbable Stent to Treat Benign Bile Duct Stenosis." Japanese Journal of Gastroenterological Surgery 40, no. 8 (2007): 1548. http://dx.doi.org/10.5833/jjgs.40.1548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Waksman, Ron, and Rajbabu Pakala. "Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent." EuroIntervention 5, F (December 2009): F36—F42. http://dx.doi.org/10.4244/eijv5ifa6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Alfonso, Fernando, Javier Cuesta, Marcos García-Guimaraes, Teresa Bastante, Ramón Maruri, and Fernando Rivero. "Treatment of coronary stent restenosis with drug-eluting bioabsorbable magnesium scaffolds." Coronary Artery Disease 28, no. 7 (November 2017): 627–28. http://dx.doi.org/10.1097/mca.0000000000000517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Talja, Martti, Markku Multanen, Tero Välimaa, and Pertti Törmälä. "Bioabsorbable SR-PLGA Horn Stent after Antegrade Endopyelotomy: A Case Report." Journal of Endourology 16, no. 5 (June 2002): 299–302. http://dx.doi.org/10.1089/089277902760102785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Miyazawa, Mitsuo, Masayasu Aikawa, Katsuya Okada, Yoshihide Otani, Isamu Koyama, Yoshito Ikada, and Yasuko Toshimitsu. "S1790 Development of a Bioabsorbable Stent to Treat Benign Biliary Stenosis." Gastroenterology 134, no. 4 (April 2008): A—270. http://dx.doi.org/10.1016/s0016-5085(08)61257-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ginsberg, Gregory, Constantin Cope, Janak Shah, Tanisha Martin, Anthony Carty, Perry Habecker, Carol Kaufmann, Claude Clerc, Juha-Pekka Nuutinen, and Pertti Törmälä. "In vivo evaluation of a new bioabsorbable self-expanding biliary stent." Gastrointestinal Endoscopy 58, no. 5 (November 2003): 777–84. http://dx.doi.org/10.1016/s0016-5107(03)02016-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Sanan, Akshay, and Sam P. Most. "A Bioabsorbable Lateral Nasal Wall Stent for Dynamic Nasal Valve Collapse." Facial Plastic Surgery Clinics of North America 27, no. 3 (August 2019): 367–71. http://dx.doi.org/10.1016/j.fsc.2019.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lin, Wenjiao, Gui Zhang, Ping Cao, Deyuan Zhang, Yufeng Zheng, Rangxiu Wu, Li Qin, Geqi Wang, and Taoyuan Wen. "Cytotoxicity and its test methodology for a bioabsorbable nitrided iron stent." Journal of Biomedical Materials Research Part B: Applied Biomaterials 103, no. 4 (July 26, 2014): 764–76. http://dx.doi.org/10.1002/jbm.b.33246.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Tang, Dennis M., Christopher R. Roxbury, Raj Sindwani, Varun R. Kshettry, Pablos Recinos, and Troy D. Woodard. "Multiple bioabsorbable corticosteroid-eluting stent placement with associated skull base injury." Laryngoscope 129, no. 7 (December 30, 2018): 1494–96. http://dx.doi.org/10.1002/lary.27659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!